Printer Friendly

PHARMACEUTICAL RESOURCES' QUAD UNIT COMPLETES SALE OF MANUFACTURING FACILITY

 PHARMACEUTICAL RESOURCES' QUAD UNIT COMPLETES
 SALE OF MANUFACTURING FACILITY
 SPRING VALLEY, N.Y., July 27 /PRNewswire/ -- Pharmaceutical Resources Inc. (NYSE PSE: PRX) announced today that its subsidiary, Quad Pharmaceuticals, Inc., has completed its previously announced sale of the injectable drug manufacturing facility formerly operated by Quad in Indianapolis, together with the adjoining real property and certain fixtures related to the facility.
 The purchaser in the transaction is a wholly owned subsidiary of The Liposome Company, Inc., a company engaged in the development of proprietary parenteral pharmaceuticals.
 Kenneth I. Sawyer, president of Pharmaceutical Resources, Inc. noted that one of the benefits of the transaction is that both Quad and PRI's principal operating subsidiary, Par Pharmaceutical, Inc. were relieved of all their obligations under the industrial development bond that had covered the real property. Sawyer further noted that completion of this transaction would allow PRI and Par to focus their full resources and efforts toward the continued growth and success of the company.
 Pharmaceutical Resources, Inc. is the parent company of Par Pharmaceutical, Inc., a manufacturer and marketer of prescription and over-the-counter generic drugs.
 -0- 7/27/92
 /CONTACT: Richard J. Nadler or Michael A. Swit, Esq. of Pharmaceutical Resources, 914-425-7100/
 (PRX) CO: Pharmaceutical Resources Inc. ST: New York IN: MTC SU: TNM


TS-SB -- NY052 -- 3433 07/27/92 10:43 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 27, 1992
Words:220
Previous Article:SOFTWARE COMPANIES FIND HARD REVENUE RULES DON'T APPLY IN INTERNATIONAL TAX
Next Article:NOTE FROM JIM MARSHALL, U.S. EPA REGION 2, EXTERNAL PROGRAMS DIVISION DIRECTOR:
Topics:


Related Articles
PAR PHARMACEUTICAL AND SUBSIDIARY REQUEST FDA TO WITHDRAW APPLICATIONS
PHARMACEUTICAL RESOURCES REPORTS YEAR-END RESULTS
PHARMACEUTICAL RESOURCES SUBSIDIARY SIGNS LETTER OF INTENT
PHARMACEUTICAL RESOURCES REPORTS FIRST QUARTER PROFIT
PHARMACEUTICAL RESOURCES' QUAD UNIT TO SELL INDIANAPOLIS MANUFACTURING FACILITIES
PHARMACEUTICAL RESOURCES REPORTS THIRD QUARTER PROFIT ON 62 PERCENT INCREASE IN SALES
PHARMACEUTICAL RESOURCES REPORTS COURT OF APPEALS DECISION
PHARMACEUTICAL RESOURCES, INC. ANNOUNCES SETTLEMENT OF LAWSUIT WITH MYLAN LABORATORIES, INC.
PHARMACEUTICAL RESOURCES REPORTS FIRST QUARTER 1995 RESULTS
ICN Acquires Third Russian Pharmaceutical Company

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters